SCHEDULE: Empery Asset Management Discloses 9.99% Stake in Theriva Biologics
Beneficial Ownership Report
Empery Asset Management, LP, along with its managing members Ryan M. Lane and Martin D. Hoe, has disclosed a 9.99% beneficial ownership stake in Theriva Biologics, Inc., including shares issuable from warrants.
Summary
- Empery Asset Management, LP, Ryan M. Lane, and Martin D. Hoe collectively reported beneficial ownership of 953,185 shares of Theriva Biologics, Inc. Common Stock.
- This aggregate ownership represents 9.99% of the company's outstanding Common Stock.
- The reported stake includes 482,154 shares of Common Stock that are issuable upon the exercise of warrants.
- The percentage is calculated based on 9,059,241 shares of Common Stock outstanding as of June 17, 2025, as reported in the company's Prospectus Supplement filed on June 20, 2025.
- A 'Blocker' provision prevents the Reporting Persons from exercising warrants to the extent that their beneficial ownership would exceed 9.99% of the outstanding Common Stock.
Sentiment
Score: 7
Explanation: The disclosure of a significant 9.99% passive stake by an investment manager generally indicates a vote of confidence in the company's long-term prospects, although the filing itself is purely factual and does not contain performance data.
Risks
- The Reporting Persons are subject to a 'Blocker' provision, which prevents them from exercising warrants if it would result in their beneficial ownership exceeding 9.99% of the outstanding Common Stock.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by an asset management firm in a biotechnology company, which is a common occurrence in the sector as institutional investors take positions in publicly traded biopharmaceutical firms.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially share price.
Key Dates
| Date | Description |
|---|---|
| 06/17/2025 | Date as of which 9,059,241 shares of Common Stock were outstanding, used for percentage calculation. |
| 06/20/2025 | Date the Company's Prospectus Supplement was filed, reporting outstanding shares. |
| 06/30/2025 | Date of event which required the filing of this statement. |
| 07/31/2025 | Date the Joint Filing Agreement and Schedule 13G were signed. |
Keywords
Theriva Biologics, Empery Asset Management, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Investment Management, Biologics, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.